Johnson & Johnson (NYSE:JNJ) unit Janssen-Cilag International NV has submitted an extension application to the European Medicines Agency (EMA) seeking approval for a subcutaneously administered formulation of multiple myeloma med DARZALEX (daratumumab).
The formulation is based on Halozyme Therapeutics’ (NASDAQ:HALO) ENHANZE technology.
The company filed an application in the U.S. a week ago.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.